Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Cost-effectiveness and Economic Benefit of Continuous Professional Development for Drug Prescribing
Cook, David A. , Stephenson, Christopher R. , Wilkinson, John M. , Foo, Jonathan , Foo, J , Maloney, Stephen

Mayo Clinic

JAMA Network Open | January 26, 2022 | Volume: 5 | Issue: 1 | Pages: e2144973

10.1001/jamanetworkopen.2021.44973 | PMID 35080604 Get It

Prospective Endoscopic Activity Assessment for Eosinophilic Gastritis in a Multisite Cohort
Hirano, Ikuo , King, Eileen, Sun, Qin , Chehade, Mirna , Abonia, J. Pablo , Bonis, Peter A, Capocelli, Kelly E., Dellon, Evan S. , Gonsalves, Nirmala , Gupta, Sandeep K. , Leung, John , Katzka, David A. , Menard‐Katcher, Paul , Khoury, Paneez , Shoda, Tetsuo, Rudman-Spergel, Amanda K., Spergel, Jonathan A., Rothenberg, Marc E., Aceves, Seema S. , Furuta, Glenn T. , investigators, CEGIR, Katzka, David, Collins, Margaret H. , Falk, Gary W. , Klion, Amy D. , Mukkada, Vincent A. , Peterson, Kathryn A. , Shoda, Tetsuo , Spergel, Jonathan A., Yang, Guang‐Yu , investigators, CEGIR

Mayo Clinic

American Journal of Gastroenterology | January 26, 2022 | Volume: 117 | Issue: 3 | Pages: 413-423

10.14309/ajg.0000000000001625 | PMID 35080202 Get It

INTRODUCTION: Eosinophilic gastritis (EG) is a chronic inflammatory disease of the stomach characterized by eosinophil-predominant gastric mucosal inflammation and gastrointestinal symptoms. The aim of this study was to prospectively evaluate endoscopic features in a large series of children and adults with EG to better understand the endoscopic manifestations and develop a standardized instrument for investigations. METHODS: Data were prospectively collected as part of the Consortium for Eosinophilic Gastrointestinal Disease Researchers, a national collaborative network. Endoscopic features were prospectively recorded using a system specifically developed for EG, the EG Endoscopic Reference System (EG-REFS). Correlations were made between EG-REFS and clinical and histologic features. RESULTS: Of 98 patients with EG, 65 underwent assessments using EG-REFS. The most common findings were erythema (72%), raised lesions (49%), erosions (46%), and granularity (35%); only 8% of patients with active histology (≥30 eosinophils/high-power field) exhibited no endoscopic findings. A strong correlation between EG-REFS scores and physician global assessment of endoscopy severity was demonstrated (Spearman r = 0.84, P < 0.0001). The overall score and specific components of EG-REFS were more common in the antrum than in the fundus or body. EG-REFS severity was significantly correlated with active histology, defined by a threshold of ≥30 eosinophils/high-power field ( P = 0.0002). DISCUSSION: Prospective application of EG-REFS identified gastric features with a strong correlation with physician global assessment of endoscopic activity in EG. Endoscopic features demonstrated greater severity in patients with active histology and a predilection for the gastric antrum. Further development of EG-REFS should improve its utility in clinical studies.
INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib
Schöffski, Patrick , Razak, Albiruni Ryan Abdul, Attia, Steven , Cesne, Axel Le, Su, Ying , Meade, Julie Nicole, Wang, Tao , Sherman, Matthew L. , Ruiz‐Soto, Rodrigo , Heinrich, Michael C. , Jones, Robin L. , Gelderblom, Hans , George, Suzanne , Mehren, Margaret von , Zalcberg, John , Kang, Yoon‐Koo , Trent, Jonathan C. , Blay, Jean‐Yves , Bauer, Sebastian

Mayo Clinic

Journal of Clinical Oncology | January 25, 2022 | Volume: 40 | Issue: 36_suppl | Pages: 359881-359881

10.1200/jco.2022.40.36_suppl.359881 Get It

359881 Background: Sunitinib is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib, a broad-spectrum KIT and PDGFRA switch-control tyrosine kinase inhibitor (TKI), is indicated for the treatment of adult patients (pts) with GIST who received prior treatment with 3 or more TKIs, including imatinib. We compared the efficacy and safety of ripretinib vs sunitinib in pts with advanced GIST who progressed on or were intolerant to imatinib. Methods: This multicenter, global, randomized, open-label phase 3 study (NCT03673501) enrolled adult pts with GIST who progressed on or had intolerance to imatinib. Pts were randomized 1:1 to ripretinib 150 mg once daily (QD) or sunitinib 50 mg QD (4 wks on/2 wks off). Randomization was stratified by KIT mutational status and imatinib intolerance. The primary endpoint was progression-free survival (PFS) by independent radiologic review (IRR) using modified RECIST version 1.1. Key secondary endpoints were objective response rate (ORR) by IRR and overall survival (OS). Hierarchical testing was performed for primary and key secondary endpoints in a prespecified sequence; testing pts with a KIT exon 11 primary mutation (Ex11 intention-to-treat [ITT] population) preceded the all-patient (AP) ITT population. Data cutoff was 1 Sep 2021; final analyses of PFS and ORR and the first interim analysis of OS were conducted. Results: A total of 453 pts were randomized to ripretinib (n = 226; Ex11 ITT, n = 163) or sunitinib (n = 227; Ex11 ITT, n = 164). Median age was 60 yrs (range 18–88) and most pts were white (66.2%) males (62.0%). PFS was not statistically different between ripretinib and sunitinib in the Ex11 ITT (hazard ratio [HR] 0.88, 95% CI 0.66, 1.16; P = 0.36; median 8.3 vs 7.0 mos) or in the AP populations (HR 1.05, 95% CI 0.82, 1.33; P = 0.72; median 8.0 vs 8.3 mos). ORR was numerically higher for ripretinib vs sunitinib in the Ex11 ITT (23.9% vs 14.6%; difference 9.3%, 95% CI 0.7, 17.8; nominal P = 0.03) and AP ITT populations (21.7% vs 17.6%; difference 4.2%, 95% CI −3.2, 11.5; nominal P = 0.27). OS data was highly immature; median OS was not reached in either arm. Fewer pts in the ripretinib arm experienced Grade 3-4 (G3-4) treatment-emergent adverse events (TEAEs) vs sunitinib (41.3% vs 65.6%). Among G3-4 TEAEs with a difference ≥5% between arms, ripretinib had fewer events vs sunitinib (hypertension [8.5% vs 26.7%], palmar-plantar erythrodysesthesia [1.3% vs 10.0%], neutropenia [0% vs 6.3%], and neutrophil count decreased [0% vs 7.2%]). Conclusions: The PFS in both arms was longer than PFS achieved by sunitinib in its pivotal phase 3 trial. While the PFS for ripretinib did not meet the primary endpoint of superiority vs sunitinib, meaningful clinical activity and fewer G3-4 TEAEs were observed in pts with advanced GIST treated with ripretinib after imatinib failure. Clinical trial information: NCT03673501.
Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
León, José de , Schoretsanitis, Georgios , Smith, Robert L. , Molden, Espen , Solismaa, Anssi , Seppälä, Niko , Kopeček, Miloslav , Švancer, Patrik , Olmos, I. Cánovas , Ricciardi, Carina , Iglesias-Alonso, Ana , Ruan, Can‐Jun , Wang, Chuanyue , Wang, Gang , Tang, Yi‐lang , Kim, Yong Sik , Kim, Se Hyun , Jung–Cook, Helgi , Nielsen, Jimmi , Verdoux, Hélène , Quilès, Clélia , Cohen, Dan , Schulte, Peter F.J. , Chopra, Nitin , McCollum, Betsy , Shelton, Charles , Cotes, Robert O. , Kaithi, Arun R., Farooq, Saeed , Ng, Chee H. , Bilbily, John , Lana, Fernando , Rădulescu, Flavian Ștefan , Seifritz, Erich , Every‐Palmer, Susanna , Bebawi, Emmanuel , Kelly, Deanna L. , Lazáry, Judit , Torres, Rafael , Yécora, Agustín, Berardis, Domenico De , Adebayo, Richard A. , Fountoulakis, Konstantinos Ν. , Ayub, Muhammad , Silva, Alzira , Bonelli, Raphael M., Crespo‐Facorro, Benedicto , Temmingh, Henk , Decloedt, Eric , Pedro, Maria Rosel , Gründer, Gerhard , Čelofiga, Andreja , Ristić, Dragana Ignjatović , Elkis, Hélio , Siskind, Dan , Masmoudi, R. , Saffian, Shamin Mohd , Buckley, P.F. , Freudenreich, Oliver , Müller, Daniel J. , de Leon, Jose , Olmos, Ismael , Iglesias-Garcia, Celso , Iglesias-Alonso, Ana , Spina, Edoardo , Ruan, Can-Jun , Wang, Chuan-Yue , Tang, Yi-Lang , Lin, Shih-Ku , Lane, Hsien-Yuan , Kim, Yong Sik , Kim, Se Hyun , Rajkumar, Anto P , González-Esquivel, Dinora F , Jung-Cook, Helgi , Baptista, Trino , Rohde, Christopher , Nielsen, Jimmi , Verdoux, Hélène , Quiles, Clelia , Sanz, Emilio J , De Las Cuevas, Carlos , Cohen, Dan , Schulte, Peter F J , Ertuğrul, Aygün , Anıl Yağcıoğlu, A Elif , Chopra, Nitin , McCollum, Betsy , Shelton, Charles , Cotes, Robert O , Kane, John M , Farooq, Saeed , Ng, Chee H , Bilbily, John , Hiemke, Christoph , López-Jaramillo, Carlos , McGrane, Ian , Lana, Fernando , Eap, Chin B , Every-Palmer, Susanna , Bousman, Chad A , Bebawi, Emmanuel , Bhattacharya, Rahul , Kelly, Deanna L , Otsuka, Yuji , Lazary, Judit , Motuca, Mariano , Chan, Sherry K W , Zolezzi, Monica , Ouanes, Sami , De Berardis, Domenico , Grover, Sandeep , Procyshyn, Ric M , Adebayo, Richard A , Kirilochev, Oleg O , Soloviev, Andrey , Fountoulakis, Konstantinos N , Wilkowska, Alina , Cubała, Wiesław J , Ayub, Muhammad , Silva, Alzira , Villagrán-Moreno, José M , Crespo-Facorro, Benedicto , Temmingh, Henk , Decloedt, Eric , Pedro, Maria R , Takeuchi, Hiroyoshi , Tsukahara, Masaru , Gründer, Gerhard , Sagud, Marina , Celofiga, Andreja , Ignjatovic Ristic, Dragana , Ortiz, Bruno B , Elkis, Helio , Pacheco Palha, António J , LLerena, Adrián , Fernandez-Egea, Emilio , Siskind, Dan , Weizman, Abraham , Masmoudi, Rim , Mohd Saffian, Shamin , Leung, Jonathan G , Buckley, Peter F , Marder, Stephen R , Citrome, Leslie , Freudenreich, Oliver , Correll, Christoph Ulrich , Müller, Daniel J , Kopecek, Miloslav , Schoretsanitis, Georgios , García, Celso Iglesias , Rajkumar, Anto P. , González‐Esquivel, Dinora F. , Rohde, Christopher , Sanz, Emílio J. , Cuevas, Carlos De las , Yağcıoğlu, A. Elif Anıl , Kane, John M. , Hiemke, Christoph , López‐Jaramillo, Carlos , McGrane, Ian R. , Arrojo, Manuel , Bousman, Chad , Bhattacharya, Rahul , Motuca, Mariano , Chan, Sherry Kit Wa , Кирилочев, О.О. , Soloviev, A. G. , Wilkowska, Alina , Cubała, Wiesław Jerzy , Tsukahara, Masaru , Ortiz, Bruno Bertolucci , LLerena, Adrián , Leung, Jonathan G. , Citrome, Leslie

Mayo Clinic

Pharmacopsychiatry | January 20, 2022 | Volume: 55 | Issue: 02 | Pages: e1-e1

10.1055/a-1737-1527 | PMID 35052001 Get It

Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer
Kishan, Amar U. , Steigler, Alison, Zapatero, A. , Guerrero, A., Joseph, David , Maldonado, Xavier , Wong, J.K. , Stish, Bradley J. , Dess, Robert T. , Pilar, Avinash , Wedde, Trude B. , Lilleby, Wolfgang , Fiano, Ryan , Stock, Richard G. , Demanes, D. Jeffrey, Martin, Santiago, Krauss, Daniel , Abu‐Isa, Eyad, Pisansky, Thomas M. , Choo, C. Richard, Greco, Stephen , Deville, Curtiland , McNutt, Todd , DeWeese, Theodore L. , Ross, Ashley E. , Ciezki, Jay P. , Karnes, R. Jeffrey , Tosoian, Jeffrey J. , Nickols, Nicholas G. , Bhat, Prashant , Shabsovich, David , Juarez, Jesus E. , Martin, Ting , Philipson, R., Chang, Albert J. , Kupelian, Patrick A. , Feng, Felix Y. , Reiter, Robert E. , Steinberg, Michael L. , Elashoff, David , Horwitz, Eric M. , Tendulkar, Rahul D. , Spratt, Daniel E. , Romero, Tahmineh , Davis, Brian J. , Deville, Curtiland , Spratt, Daniel E , Dess, Robert T , Ma, Ting Martin , Steigler, Allison , Denham, James William , Reddy, Chandana A. , Merrick, Gregory Stephen , Moran, Brian Joseph , Tran, Phuoc T , Martínez‐Monge, Rafael , Song, Daniel Y. , Tilki, Derya , Jiang, Tommy , Xiang, Michael H. , Rettig, Matthew B. , Berlin, Alejandro , Tward, Jonathan D. , Boutros, Paul C.

Mayo Clinic

JAMA Oncology | January 20, 2022 | Volume: 8 | Issue: 3 | Pages: e216871

10.1001/jamaoncol.2021.6871 | PMID 35050303 Get It

CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer
Shepherd, Jonathan H. , Ballman, Karla, Polley, Mei‐Yin C. , Campbell, Jordan D., Fan, Cheng, Selitsky, Sara, Fernández-Martínez, Aranzazu , Parker, Joel S., Hoadley, Katherine A. , Li, Yan, Soloway, Matthew G., Spears, Patricia A., Singh, Baljit, Tolaney, Sara M. , Somlo, George, Port, Elisa R. , Cynthia, X. , Kuzma, Charles, Mamounas, Eleftherios, Golshan, Mehra, Bellon, Jennifer R. , Hahn, Olwen M., Hudis, Clifford A. , Hyslop, Terry, Perou, Charles M. , Sikov, William M. , Hyslop, Terry , Hu, Zhiyuan , Tolaney, Sara , Port, Elisa R , Ma, Cynthia , Bellon, Jennifer R , Collyar, Deborah , Hudis, Clifford , Winer, Eric , Partridge, Ann H , Carey, Lisa A , Perou, Charles M , Sikov, William M , Hoadley, Katherine A , Shepherd, Jonathan H. , Ballman, Karla, Polley, Mei-Yin , Campbell, Jordan D., Fan, Cheng, Selitsky, Sara, Fernandez-Martinez, Aranzazu , Parker, Joel S., Li, Yan, Soloway, Matthew G., Spears, Patricia A., Singh, Baljit, Somlo, George, Kuzma, Charles, Mamounas, Eleftherios, Golshan, Mehra, Hahn, Olwen M.

Mayo Clinic

Journal of Clinical Oncology | January 19, 2022 | Volume: 40 | Issue: 12 | Pages: 1323-1334

10.1200/jco.21.01506 | PMID 35044810 Get It

PURPOSE CALGB 40603 ( NCT00861705 ), a 2 × 2 randomized phase II trial, demonstrated that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin and cyclophosphamide significantly increased the pathologic complete response (pCR) rate in stage II-III triple-negative breast cancer. We now report long-term outcomes (LTOs) and correlative science end points. PATIENTS AND METHODS The Kaplan-Meier method was used to estimate LTOs in 443 patients who initiated study treatment. Log-rank tests and Cox proportional hazards models evaluated the impact of clinical characteristics, pathologic response, calculated residual cancer burden (RCB) in patients with residual disease (RD), treatment assignment, and dose delivery during wP on LTOs, including event-free survival (EFS). Genomic predictors of treatment response and outcomes were assessed on pretreatment tumor samples by mRNA sequencing. RESULTS Among baseline characteristics, only the clinical stage was associated with LTOs. At a median follow-up of 7.9 years, LTOs were not significantly improved with either carboplatin or bevacizumab, overall or in patients with basal-like subtype cancers by genomic analysis. Patients with pCR (n = 205, 46.3%) had significantly higher 5-year EFS (85.5% v 56.6%, log-rank P < .0001) and overall survival (87.9% v 63.4%, P < .0001) rates compared with patients with RD, even those with RCB class I. Among clinical and genomic features, evidence of immune activation, including tumor-infiltrating lymphocytes and low B-cell receptor evenness, was associated with pCR and improved EFS. CONCLUSION Despite higher pCR rates, neither carboplatin nor bevacizumab appeared to improve LTOs although the study was not powered to assess these secondary end points. pCR was associated with superior LTOs even when compared with minimal RD. Markers of immune activation in pretreatment tumor biopsies were independently associated with higher pCR rates and improved survival.
Association of Area-Level Socioeconomic Deprivation With Hypoglycemic and Hyperglycemic Crises in US Adults With Diabetes
Heien, Herbert C., Sangaralingham, Lindsey R. , Inselman, Jonathan , Shah, Nilay D. , Kurani, Shaheen Shiraz, Inselman, Jonathan W, Kurani, Shaheen , Golden, Sherita Hill , McCoy, Rozalina G.

Mayo Clinic

JAMA Network Open | January 18, 2022 | Volume: 5 | Issue: 1 | Pages: e2143597

10.1001/jamanetworkopen.2021.43597 | PMID 35040969 Get It

Medial Temporal Atrophy in Posterior Cortical Atrophy and Its Relationship to the Cingulate Island Sign
Josephs, Kennedy A., Pham, Nha Trang Thu, Graff‐Radford, Jonathan , Lowe, Val J. , Whitwell, Jennifer L., Machulda, Mary M. , Whitwell, Jennifer

Mayo Clinic

Journal of Alzheimer's Disease | January 18, 2022 | Volume: 86 | Issue: 1 | Pages: 491-498

10.3233/jad-215263 | PMID 35068459 Get It

Background: It has been hypothesized that medial temporal sparing may be related to preserved posterior cingulate metabolism and the cingulate island sign (CIS) on [18F]fluorodeoxyglucose (FDG) PET in posterior cortical atrophy (PCA). Objective: To assess the severity of medial temporal atrophy in PCA and determine whether the presence of a CIS is related to medial temporal sparing. Methods: Fifty-five PCA patients underwent MRI and FDG-PET. The degree and symmetry of medial temporal atrophy on MRI was visually assessed using a five-point scale for both hemispheres. Visual assessments of FDG-PET coded the presence/absence of a CIS and whether the CIS was symmetric or asymmetric. Hippocampal volumes and a quantitative CIS were also measured. Results: Medial temporal atrophy was most commonly mild or moderate, was symmetric in 55% of patients, and when asymmetric was most commonly worse on the right (76%). Older age and worse memory performance were associated with greater medial temporal atrophy. The CIS was observed in 44% of the PCA patients and was asymmetric in 50% of these. The patients with a CIS showed greater medial temporal asymmetry, but did not show lower medial temporal atrophy scores, compared to those without a CIS. Hippocampal volumes were not associated with quantitative CIS. Conclusion: Mild medial temporal atrophy is a common finding in PCA and is associated with memory impairment. However, medial temporal sparing was not related to the presence of a CIS in PCA.
Phase II Trial of Bevacizumab Monotherapy in Pancreatic Neuroendocrine Tumors
Zhu, Mojun, Costello, Brian A., Yin, Jun, Pettinger, Adam M., Strosberg, Jonathan R., Erlichman, Charles, Hobday, Timothy J., Zhu, Mojun, Costello, Brian A., Yin, Jun, Pettinger, Adam M., Strosberg, Jonathan R., Erlichman, Charles, Hobday, Timothy J.

Mayo Clinic

Pancreas | January 18, 2022 | Volume: 50 | Issue: 10 | Pages: 1435-1439

10.1097/mpa.0000000000001950 | PMID 35041344 Get It

Objectives Systemic therapies for pancreatic neuroendocrine tumors (PNETs) are limited. The combination of bevacizumab and temsirolimus showed significant antitumor activity, but the single-agent activity of bevacizumab was unknown. We conducted a single-arm, phase II trial to evaluate the efficacy of bevacizumab in PNETs. Methods Patients with progressive disease by the Response Evaluation Criteria in Solid Tumors version 1.1 within 7 months of enrollment were eligible for bevacizumab 10 mg/kg every 2 weeks. Adverse events were assessed according to the Common Terminology Criteria for Adverse Events version 3.0. The primary end point was response rate (RR). Results Twenty-four patients were enrolled and followed up for a median duration of 36.1 months. Confirmed RR was 12.5%; 75.0% of patients had stable disease at 6 months. Median progression-free survival was 18.0 months; median overall survival was not reached. Common grade 3 adverse events were hypertension (45.8%) and proteinuria (8.3%). No grade 4 adverse events were observed. Conclusions Bevacizumab demonstrated promising antitumor activity in progressive PNETs comparable to standard targeted therapy. Although this study failed to reject the null hypothesis (RR, 10%), bevacizumab seems a reasonable monotherapy and a potential component of combination therapies given clinical activity and low rates of adverse events.